FLSM
Frazier Life Sciences Management Portfolio holdings
AUM
$2.5B
This Quarter Return
-3.63%
1 Year Return
+52.94%
3 Year Return
+530.54%
5 Year Return
–
10 Year Return
–
AUM
$2.14B
AUM Growth
+$2.14B
(-9.8%)
Cap. Flow
-$56.2M
Cap. Flow
% of AUM
-2.63%
Top 10 Holdings %
Top 10 Hldgs %
61.97%
Holding
57
New
7
Increased
13
Reduced
4
Closed
8
Top Buys
| 1 |
Disc Medicine
IRON
|
$43.7M |
| 2 |
Erasca
ERAS
|
$38.3M |
| 3 |
AnaptysBio
ANAB
|
$31.7M |
| 4 |
Ultragenyx Pharmaceutical
RARE
|
$17.5M |
| 5 |
Savara
SVRA
|
$16.8M |
Top Sells
Sector Composition
| 1 | Healthcare | 99.8% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
DCPH
51
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| – | – |
-1,455,837
| Closed | -$22.9M |
|
|
GRTS
52
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
| – | – |
-1,030,878
| Closed | -$2.65M |
|
53
Intellia Therapeutics
NTLA
$1.26B
| – | – |
-203,684
| Closed | -$5.6M |
|
54
Structure Therapeutics
GPCR
$1.14B
| – | – |
-629,194
| Closed | -$27M |
|
|
BLUE
55
DELISTED
bluebird bio
BLUE
| – | – |
-1,709,907
| Closed | -$2.19M |
|
|
JBIO
56
Jade Biosciences, Inc. Common Stock
JBIO
$245M
| – | – |
-1,204,867
| Closed | -$35.6M |
|
57
Apellis Pharmaceuticals
APLS
$3.51B
| – | – |
-885,165
| Closed | -$52M |
|